Published in TB and Outbreaks Week, April 22nd, 1996
An update on USPHS Study 22, also known as the Rifapentine Clinical Trial, was published in the CDC's winter 1996 TB Notes.
The controlled, randomized, open-label trial is now underway to compare the efficacy and safety of the two regimens.
Regimen 1 consists of standard twice-weekly therapy with high-dose isoniazid (900 mg) and rifampin (600 mg). ...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.